

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



January 14, 2025

Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP]

Company name: Chordia Therapeutics Inc.
 Listing: Tokyo Stock Exchange
 Security Code: 190A
 URL: [https:// www.chordiatherapeutics.com/en/](https://www.chordiatherapeutics.com/en/)
 Representative: Hiroshi Miyake, CEO & Representative Director
 Inquiries: Kentaro Kume, CFO
 Telephone: +81-3-6661-9543
 Preparation of supplementary material on financial results: None
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Non-consolidated financial results for the Three Months ended November 30, 2024 (from September 1, 2024 to November 30, 2024)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes)

	Business revenue		Operating profit		Ordinary profit		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended November 30, 2025	-	-	-624	-	-615	-	-616	-
November 30, 2024	-	-	-	-	-	-	-	-

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended November 30, 2025	-9.07	-
November 30, 2024	-	-

NOTE 1. The first quarter of the fiscal year ended August 31, 2024 has not prepared a quarterly financial table, so the description of the first quarter of the fiscal year ended August 2024 was included. And the rate of change from the same quarter of the previous fiscal year for the first quarter of the fiscal year ended August 2025 is not shown.

2. In terms of quarterly net profit per share after adjustment for latent stocks in the third quarter of the fiscal year ended August 31, 2025, latent stocks still exist. However, net loss per share is not stated because it is a quarterly loss.

(2) Non-consolidated financial position

	Total assets	Business revenue	Equity Ratio
As of	Millions of yen	Millions of yen	%
November 30, 2024	3,784	3,567	94.2
August 31, 2024	4,632	4,161	89.8

Reference : Equity
 As of November 30, 2024 3,564 million yen
 As of August 31, 2024 4,158 million yen

2. Cash dividends

	Dividend per share				
	End of first quarter	End of second quarter	End of the third quarter	Term end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended August 31, 2024	-	0.00	-	0.00	0.00
Fiscal year ending August 31, 2025	-				
Fiscal year ending August 31, 2025 (Forecast)		0.00	-	0.00	0.00

3. Forecast of non-consolidated financial results for the fiscal year ending August 31, 2025 (from September 1, 2024 to August 31, 2025)

(Percentages indicate year-on-year changes)

	Business revenue		Operating income		Ordinary income		Net income		Per share Net income
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	-	-	-2,434	-	-2,378	-	-2,380	-	-35.17

Note:

(1) Application of special accounting methods for preparing financial statements: None

(2) Changes in accounting policies and changes or restatement of accounting estimates

- A) Changes in accounting policies due to revision of accounting standards: None
- B) Changes in accounting policies other than the above: None
- C) Changes in accounting estimates: None
- D) Restatement of revisions: None

(3) Number of shares outstanding (common shares)

- A) Number of shares outstanding at the end of the period (including treasury stock)
 - 1st Quarter FY8/2025 68,208,800 Shares
 - FY8/2024 67,678,800 Shares
- B) Number of treasury stock at the end of the period
 - 1st Quarter FY8/2025 - Shares
 - FY8/2024 - Shares
- C) Average number of shares outstanding
 - 1st Quarter FY8/2025 67,990,866 Shares
 - 1st Quarter FY8/2024 - Shares

* Review of attached financial result by a certified public accountant or an auditing firm: Held

* Proper use of earning forecasts and other special matters

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Actual results may differ from the above forecasts due to changes in business performance and other factors. Please refer to "1. Qualitative Information on Financial Results, (3) Explanation of Earnings Forecasts and Other Forward-looking Statements" on page 2 of the attached material for notes on these of financial results forecasts.

Attached Material

Index

1. Qualitative information regarding financial results for the Three Months ended November 30, 2024 (from September 1, 2024 to November 30, 2024).....	2
(1) Explanation of operating results	2
(2) Explanation of financial position	2
(3) Explanation of earnings forecasts and other forward-looking statements	3
2. Quarterly financial statement and significant notes thereto.....	
(1) Quarterly balance sheet.....	4
(2) Statement of income.....	5
(Cumulative)	
(3) Notes to financial statements.....	6
Notes on premise of going concern.....	6
Notes on Per Share information.....	6
Notes on Segment information.....	6
Notes on Quarterly cash flows.....	6

1. Qualitative Information regarding financial result for the fiscal year ended August 31, 2024

(1) Explanation of operating results

The Company aspires to build a world where people can feel hope for tomorrow under its slogan of “Building a World where Tomorrow is Another Day by delivering first-in-class anticancer drugs to patients as soon as possible. Since our establishment, our mission has been to discover innovative (first-in-class) anticancer drugs. Through the realization of this mission, our vision is to grow into the world's first R&D-oriented pharmaceutical company, originating from Japan by 2030.

We are pursuing drug discovery research specializing in oncology, where there are high unmet medical needs with a focus on novel, small-molecular innovative drugs (first-in-class), which have a totally new mechanism of action. Since first-in-class drugs have a novel mechanism of action, they are expected to demonstrate a different clinical benefit compared to existing drugs and have the potential to drastically change the current standard of care. In particular, for many patients who are anxious about the progress of their current cancer and are not sufficiently satisfied with their treatment because of the lack of adequate efficacy of existing drugs, we have been promoting business with the goal of delivering the hope that they will be able to control the progression of their cancer.

During the first quarter of the fiscal year, 2024, our research and development five pipelines demonstrated steady progress, particularly CDC-like kinase (CLK) inhibitor rogocekib (“rogocekib”).

Regarding rogocekib, the ongoing Phase 1 part of Phase 1/2 clinical trial for hematologic malignancies in the U.S. is progressing well, with five additional patients added during the quarter from the 20 patients enrolled as of August 31, 2024, for a total of 25 patients enrolled as of November 30, 2024. We are currently working on further trial progress. In addition to the progress of clinical trials, in November 2024, rogocekib was released under the International Nonproprietary Name (INN) as a recommended INN (rINN) as a recommended INN (rINN). We recognize this as a step forward in our activities toward commercialization.

Based on the license agreement signed with Ono in December 2020, Ono is steadily advancing clinical trials for CTX-177, a MALT1 inhibitor (“CTX-177”). It is currently conducting phase 1 clinical trials in the United States and Japan for patients with relapsed or refractory non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

The CDK12 inhibitor CTX-439 (“CTX-439”), which is currently in the preclinical stage, has completed safety studies and manufacturing of the investigational drug substance in preparation for the start of clinical trials, and has received funding from AMED and other sources.

In addition to promoting in-house research and development of CTX-439 and GCN2 inhibitors (“GCN-2”), we are also proactively considering a wide range of possibilities, including early-stage partnering, in align with our current focus of research resources on rogocekib.

Regarding patents held by the Company, the substance patent for rogocekib is currently registered in 51 countries, the substance patent for CTX-177 has been additionally registered in 2 countries and is currently registered in 13 countries, the substance patent for CTX-439 was additionally registered in 36 countries and is now registered in 40 countries. The substance patent for GCN2 inhibitor has been registered in one additional region is now registered in 6 countries and 1 region.

As a result of the above business activities, there were no business revenues for the first quarter of this fiscal year. Regarding business expenses, research and development expenses totaled 522 million yen, and selling, general, and administrative expenses totaled 101 million yen.

As a result, operating loss for the period totaled 624 million yen, ordinary loss totaled 615 million yen, and loss totaled 616 million yen.

The company operates only one business segment (i.e., the pharmaceutical business), and therefore there are no segment-based operating results to report.

(2) Explanation of financial position

1) Assets, liabilities and net assets

Assets

Assets at the end of the first quarter totaled 3,784 million yen, a decline of 847 million yen compared with the end of the previous fiscal year. The main factor was a decline of 893 million yen in cash and deposits. Non-current assets totaled 23 million yen, an increase of 3 million yen compared with the end of the previous fiscal year.

Liabilities

Liabilities as of end of the first quarter of the fiscal year totaled 217 million yen, a decline of 253 million yen compared with the end of the previous fiscal year. Current liabilities totaled 27 million yen, a decline of 253 million yen compared with the end of the previous fiscal year. The main factor was a decline of 893 million yen in accounts payable-other. There are no non-current liabilities.

Net assets

Net assets as of the first quarter of the fiscal year totaled 3,567 million yen, a decline of 593 million yen compared with the end of the previous fiscal year. The main factor was retained earnings declined 616 million yen as a result of recording a net loss.

(3) Explanation of earnings forecasts and other forward-looking statements

There are no changes to the earnings forecasts announced in the financial results for the fiscal year ending August 2024.

3. Financial statement and significant notes thereto

(1) Balance sheet

(Thousands of yen)

	As of August 31, 2024	As of November 30, 2024
Assets		
Current assets		
Cash and deposits	4,329,624	3,436,521
Advance payments	59,657	60,899
Prepaid expenses	38,155	37,165
Others	177,981	226,272
Total current assets	4,605,418	3,760,859
Non-Current assets		
Property, plant and equipment		
Tools, furniture and fixtures	11,213	11,213
Accumulated depreciation	-8,468	-8,834
Tools, furniture, and fixtures, net	2,744	2,378
Total property, plant and equipment	2,744	2,378
Intangible assets		
Software	620	198
Total intangible assets	620	198
Investments and other assets		
Long-term prepaid expenses	11,269	8,956
Others	12,316	12,316
Total investments and other assets	23,586	21,273
Total non-current assets	26,952	23,850
Total assets	4,632,370	3,784,709
Liabilities		
Current liabilities		
Accounts payable-other	382,428	122,770
Accrued expenses	2,295	6,352
Income taxes payable	54,290	13,572
Others	32,058	74,548
Total current liabilities	471,072	217,244
Total liabilities	471,072	217,244
Net assets		
Shareholders' equity		
Share capital	845,270	856,560
Capital surplus	9,034,871	9,046,161
Retained earnings	-5,721,780	-6,338,192
Total shareholders' equity	4,158,362	3,564,529
Stock acquisition right	2,935	2,935
Total net assets	4,161,297	3,567,465
Total liabilities and net assets	4,632,370	3,784,709

(2) Statement of income

(Thousands of yen)

	<u>Ended November 30, 2024</u> (September 1, 2024 To November 30, 2024)
Business revenue	-
Cost of sales	
Research and development expense	522,422
Selling, general and administrative expenses	101,951
Total operating expenses	<u>624,374</u>
Operating profit or loss(-)	<u>-624,374</u>
Non-operating income	
Grant income	10,818
Others	67
Total non-operating income	<u>10,885</u>
Non-operating expenses	
Foreign exchange losses	2,318
Total non-operating expenses	<u>2,318</u>
Ordinary profit or loss(-)	<u>-615,807</u>
Profit or Loss(-) before income taxes	<u>-615,807</u>
Income taxes	605
Total income taxes	<u>605</u>
Net profit or loss(-)	<u>-616,412</u>

(3) Notes to financial statements

Notes on the going concern assumption

Not applicable.

Notes on the substantial changes in the amount of shareholder equity's

Not applicable.

Notes on the segment information

Disclosure of this information is omitted because the Company operates a single segment of drug development business.

Note on cash flow statement

Quarterly statements of cash flows for the first quarter of the current fiscal year have not been prepared. Depreciation and amortization (including amortization related to intangible assets) for the first quarter cumulative period are as follows.

Depreciation and amortization (3 months ended November 30, 2024)	789 thousand yen
--	------------------